Table 6.

cfDNA concentrations among tumour parameters in the breast cancer patients at time points 1 (T1) and 2 (T2).

Parameter	n	ALU 115 (ng/mL)		p-Value	ALU 247 (ng/mL)		p-Value
		T1	T2		T1	T2
Molecular Subtype
Luminal A	6	2.16 ± 0.53	1.70 ± 0.15	0.068	2.26 ± 0.78	2.19 ± 0.37	0.846
Luminal B	10	1.64 ± 0.61	1.61 ± 0.52	0.907	2.00 ± 0.79	1.94 ± 1.08	0.888
HER2-enriched	7	1.80 ± 0.88	1.60 ± 1.12	0.717	2.21 ± 0.27	1.62 ± 1.20	0.228
Triple negative	9	1.84 ±0.28	1.77 ± 0.49	0.715	2.19 ± 0.55	1.96 ± 0.66	0.433
Histological Subtype
Invasive ductal carcinoma	29	1.84 ± 0.58	1.69 ± 0.66	0.331	2.13 ± 0.71	2.01 ± 0.72	0.525
Unknown	3	1.77 ± 0.34	1.38 ± 1.84	0.736	2.01 ± 0.47	1.52 ± 0.79	0.408
Tumour Stage
Stage II	4	1.69 ± 0.82	1.64 ± 0.69	0.929	2.22 ± 0.53	1.81 ± 0.69	0.361
Stage III	25	2.05 ± 0.37	1.67 ± 0.46	0.002 *	2.23 ± 0.88	2.03 ± 0.70	0.378
Stage IV	3	1.77 ± 0.34	1.52 ± 0.79	0.641	2.01 ± 0.47	1.34 ± 1.85	0.576
Tumour Grade
Grade 1	1	1.88	1.80	-	2.05	1.93	-
Grade 2	12	1.74 ± 0.68	1.56 ± 0.88	0.581	2.24 ± 0.29	1.86 ± 0.94	0.195
Grade 3	18	2.41 ± 0.48	1.83 ± 0.43	0.005 *	2.97 ± 0.87	2.48 ± 0.81	0.089
Grade 4	1	1.39	0.60	-	2.48	1.50	-

Results were presented as mean ± SD: * p-value ≤ 0.05 is considered significant: T1 = before commencement of chemotherapy: T2 = after the 3rd cycle of chemotherapy.